{
    "root": "2f9d596e-65fa-2c97-e063-6394a90a29a3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Benznidazole",
    "value": "20250305",
    "ingredients": [
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "BENZNIDAZOLE",
            "code": "YC42NRJ1ZD"
        }
    ],
    "indications": "benznidazole tablets indicated pediatric patients 2 12 years age treatment chagas disease ( american trypanosomiasis ) caused trypanosoma cruzi . indication approved accelerated approval based number treated patients became immunoglobulin g ( igg ) antibody negative recombinant antigens t. cruzi [ ( 14 ) ] . continued approval indication may contingent upon verification description benefit confirmatory trials .",
    "contraindications": "pediatric patients 2 12 years age : total daily dose 5 mg/kg 8 mg/kg orally administered two divided doses separated approximately 12 hours duration 60 days ( 2.2 ) . full prescribing information important instructions ( 2.1 , 2.3 , 2.4 ) .",
    "warningsAndPrecautions": null,
    "adverseReactions": "• history hypersensitivity reaction benznidazole nitroimidazole derivatives ( 4.1 ) . • disulfiram usage within last two weeks ( 4.2 ) . • patients cockayne syndrome ( 4.3 , 6.2 ) .",
    "indications_original": "Benznidazole Tablets are indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis) caused by \n       \n \n  Trypanosoma cruzi.  \n      \n\n \n                  This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) antibody negative against the recombinant antigens of \n       \n \n  T. cruzi [see Clinical Studies (\n        \n  \n   14)]\n       \n \n  . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",
    "contraindications_original": "Pediatric patients 2 to 12 years of age: The total daily dose is 5 mg/kg to 8 mg/kg orally administered in two divided doses separated by approximately 12 hours for a duration of 60 days ( 2.2 ). See Full Prescribing Information for important administration instructions ( 2.1 , 2.3 , 2.4 ).",
    "adverseReactions_original": "• History of hypersensitivity reaction to benznidazole or other nitroimidazole derivatives ( 4.1 ). • Disulfiram usage within the last two weeks ( 4.2 ). • Patients with Cockayne Syndrome ( 4.3 , 6.2 )."
}